2025-05-28-Jefferies-INSP管理层午餐会_SLEEP会议；6月9日（周一）于西雅图_7页_96kb

This financial research report from Jefferies analyzes Inspire Medical Systems (INSP), a company in the medical supplies and devices sector, with a focus on its equity valuation and market outlook. The event summary highlights a scheduled lunch on June 9, 2025, in Seattle during the SLEEP conference, where discussions will cover the Inspire 5 launch, hypoglossal nerve stimulator (HGNS) market trends, and competitive dynamics. Key valuation insights include a $230 price target for a 12-month period, based on a 7x multiple of projected 2025 sales, while the buy recommendation anticipates a total return of 20% or more. Downside risks identified are potential ENT capacity constraints affecting procedure growth, delays in treatment paradigms such as GLP-1 uptake or payer policy shifts, and competitive intensification from new US entrants. Additional sections detail valuation methodologies, investment ratings, and extensive disclosures on conflicts of interest and legal considerations, with no recommendation changes noted in the provided period.